51707-38-1

Basic information

• Product Name: 3,5-DIMETHOXYBENZHYDRAZIDE
• Synonyms: 3,5-DIMETHOXY BENZOIC HYDRAZIDE;3,5-DIMETHOXYBENZHYDRAZIDE;3,5-DIMETHOXYBENZOYL HYDRAZINE;3,4-Dimethoxybenzhydrazide, 98+%;3,5-DiMethoxybenzenecarbohydrazide;3,5-DIMETHOXYBENZHYD;AIDS018528;AIDS-018528
• CAS NO: 51707-38-1
• Molecular Formula: C₉H₁₂N₂O₃
• Molecular Weight: 196.2
• Product Categories: Aromatic Hydrazides, Hydrazines, Hydrazones and Oximes
• Mol File: 51707-38-1.mol
• Article Data: 19

Chemical Properties

• Melting Point: 143-144°C
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.189 g/cm³
• Refractive Index: 1.544
• PKA: 11.78±0.10(Predicted)
• CAS DataBase Reference: 3,5-DIMETHOXYBENZHYDRAZIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-DIMETHOXYBENZHYDRAZIDE(51707-38-1)
• EPA Substance Registry System: 3,5-DIMETHOXYBENZHYDRAZIDE(51707-38-1)

Safety Data

• Statements: R36/37/38:Irritating to eyes, respiratory system and skin.
• Safety Statements: S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.; S36:Wear suitable prot
• Hazardous Substances Data: 51707-38-1(Hazardous Substances Data)

Usage

General Description

3,5-Dimethoxybenzhydrazide is a chemical compound that falls under the category of benzhydrazides. It is known by its systematic name which is 3,5-dimethoxybenzene-1-carbohydrazide. The molecular formula for this compound is C9H12N2O3. It is a solid substance at room temperature, and it is commonly used in organic synthesis as a reagent in the creation of other complex chemical compounds. Its properties are based on its functional groups which include two methoxy groups (OCH3) attached to a benzene ring and a carbohydrazide moiety. Further specific details about this compound, such as its melting point, boiling point, density, etc, would need to be determined experimentally or through reliable resources.

InChI:InChI=1/C9H12N2O3/c1-13-7-3-6(9(12)11-10)4-8(5-7)14-2/h3-5H,10H2,1-2H3,(H,11,12)

Upstream product

• 99-10-5 3,5-Dihydroxybenzoic acid 
• 1132-21-4 3,5-dimethoxybenzoic acid 
• 2150-37-0 methyl 3,5-dimethoxybenzoate 
• 17275-82-0 ethyl 3,5-dimethoxybenzoate 

Downstream Products

• 75996-26-8 azido(3,5-dimethoxyphenyl)methanone 
• 54132-76-2 3,5-dimethoxyphenyl isocyanate 
• 807628-45-1 C₃₃H₃₇N₅O₇Si 
• 1219921-88-6 C₁₄H₁₈N₂O₆ 
• 1004375-56-7 C₂₁H₂₀N₂O₄ 
• 444932-31-4 2-(3,5-dimethoxybenzoyl)-N-(naphthalen-1-yl)hydrazine-1-carboxamide 
• 1254359-53-9 4-(4-methyl-piperazin-1-yl)-5-(3,5-dimethoxyphenyl)-2,4-dihydro-[1,2,4]triazole-3-thione 
• 1429183-46-9 2-(3,5-Dimethoxyphenyl)-5-((2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethyl)thio)-1,3,4-oxadiazole 
• 1610621-48-1 C₂₁H₁₉N₃O₂S₂ 
• 1610621-35-6 C₂₁H₂₁N₃O₃S₂ 
• 1610621-34-5 C₂₀H₁₉N₃O₃S₂ 
• 1610621-47-0 C₂₀H₁₇N₃O₂S₂ 
• 1430086-31-9 4-benzyl-N-[(3,5-dimethoxyphenyl)carbonyl]-2,5-dioxo-1-[(1R)-1-phenylethyl]imidazolidine-4-carbohydrazide 
• 713087-09-3 2-(5-(3,5-dimethoxyphenyl)-1,3,4-oxadiazol-2-ylthio)-1-phenylethanone 

Relevant articles and documents

Synthesis, crystal structures and insulin-like activity of three new oxidovanadium(V) complexes with aroylhydrazone ligand

Three new oxidovanadium(V) complexes were designed, synthesized and characterized by C, H, N elemental analysis, single crystal X-ray diffraction，UV/Vis and IR spectra. Complex 1: [VOL1X] (H2L1 = (E)-N′-(2-hydroxybenzylidene)-3-methbenzohydrazide, HX = ethylmaltol = 2-ethyl-3-hydroxy-4-pyrone), Complex 2: [VOL2(CH3O)(CH3OH)], (H2L2 = C16H16N2O4 = (E)-N′-(2-hydroxybenzylidene)-3,5-dimethoxybenzohydrazide, CH3OH = methanol), Complex 3: [VOL3X] (H2L3 = (E)-N′-(3-ethoxy-2-hydroxybenzylidene)-3,5-dimethoxybenzohydrazide). The insulin-like activity of the three complexes was tested. Both normal and streptozotocin (STZ)-diabetic mice were administered intragastrically for two weeks. It was found that the complexes at doses of 10.0 and 5.0 mg V·kg?1 can significantly decrease the blood glucose level in STZ-diabetic mice, and the blood glucose level in the treated normal mice was not altered. The lesions of kidney and liver caused by diabetes have varying degrees of improvement.

Synthesis, pharmacological evaluation and docking study of a new modulator of microtubule polymerization

Objectives: The main goal of this paper was to conduct the synthesis to determine cytotoxic activity and to carry out docking studies on new LASSBio-1586 isosteres. LASSBio-1586 is a new combretastatin A4 (CA4) analogue previously identified as a simple antitumor drug candidate, able to inhibit microtubule polymerization with broad in vitro and in vivo cytotoxic activity. Methods: The new isosteres (7b-7h, 8a and 9a) were evaluated against HL-60, OVCAR-8, HCT8 and LUCENA tumor cell lines, using cytotoxic test of MTT. The tubulin polymerization assay was performed using a tubulin polymerization assay kit from cytoskeletonR and by CEREP employing a single concentration of 10 μM. Binding mode at β-tubulin colchicine binding site was stablished by blind molecular docking studies. Results: LASSBio-1920 (7h) was identified as the most potent cytotoxic compound with IC50 values ranging from 0.75 nM to 11.5 nM, although it was inactive against MDR tumor cell line LUCENA (IC50 = 80 μM). This compound presented remarkable cytotoxic selective index in comparison with CA4 and LASSBio-1586. Its ability to modulate microtubule polymerization was confirmed and its mode of interaction with colchicine binding site in β-tubulin was demonstrated. Conclusion: Compound 7h is a new isostere of LASSBio-1586 that displayed potent cytotoxic activity and better cytotoxic selectivity index and has been shown to interact with DAMA-colchicine in its co-crystal with β-tubulin.

Design, synthesis, biological evaluation, and 3D-QSAR analysis of podophyllotoxin–dioxazole combination as tubulin targeting anticancer agents

The advancement of cancer-fighting drugs has never been a simple linear process. Those drug design professionals begin to find inspiration from the nature after failing to find the ideal products by creative drug design and high-throughput screening. To obtain new molecules for inhibiting tubulin, podophyllotoxin was adopted as the leading compound and 1,3,4-oxadiazole was brought in to the C-4 site of podophyllotoxin in this research. A series of seventeen podophyllotoxin-derived esters have been achieved and then evaluated their antitumor activities against four different cancer cell lines: A549, MCF-7, HepG2, and HeLa. Among all the compounds, compound 7c showed the best antiproliferating properties with IC50?=?2.54?±?0.82?μm against MCF-7 cancer cell line. It was obvious that the content of ROS grew significantly in MCF-7 in a way depending on the dosage. The time- and dose-dependent cell cycle assays revealed that compound 7c could apparently block cell cycle in the phase of G2/M along with the upregulation of cyclin A2 and CDK2 protein. According to further studies, confocal microscopy experiment has certified that compound 7c could restrain cancer from growing by blocking the polymerization of microtubule. Meanwhile, compound 7c could be ideally integrated with the colchicine site of tubulin. In future, it would be feasible to selectively design tubulin inhibitors with the help of 3D-QSAR. This means that it is hopeful to develop compound 7c as a potential agent against cancer due to its biological characteristics.